Fritextsökning
Innehållstyper
-
New head of Vinnova
While waiting for a new gerenal-director, Vinnova has got a substitute general-director.
-
How to be a perfect mingler
Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, ...
-
Fat cells' reaction differs with body weight
The fat cells of overweight people may react differently to dietary changes than in their lean peers, according to a pioneering study from the Dutch organizatio...
-
Tvärvetenskap tacklar genreglering
Forskare inom matematik, IT och cell- och molekylärbiologi har gjort nya upptäckter kring hur celler reglerar proteinnivåerna.
-
Snedfördelning av Europeiska forskningsrådets anslag
Risk för "brain drain" inom Europa enligt polsk professor.
-
Medicult acquires embryo scanner
The Danish company Medicult signs an agreement with Novocellus to gain access to embryo selection technology.
-
Cate Poulsen, Qiagen
Why are you going to Scanlab and Biotech Forum?
-
Gen minskar risk för KOL och astma
En internationell studie visar att både risken för KOL och barnastma minskar hos personer med en viss genvariant. Forskarna bakom studien tror på nya och bättre...
-
EU har siktet på Lundbeck
EU-kommissionen kommer att granska om den danska läkemedelsjätten har brutit mot EUs regler för konkurrens. Granskningen gäller hur Lundbeck har agerat kring ge...
-
Laboratory food
VWR exhibits laboratory tools with molecular gastronomy Rotary evaporators and magnetic stirrers - for making food. VWR tries out new ways for the exhibition at...
-
Mingling do's and don'ts
Linkedin, Facebook, MSN and Gmail are all perfect tools for the urban businessman or woman to keep track of and stay up-to-date with contacts. "But in the end, ...
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Early stage research and low turnaround dominates
Nordic science parks are full of advanced research performed by small companies but little research is done in later stages. Only a couple of the best performer...
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
Upp och ner under det andra kvartalet
Astrazeneca, Probi och Recipharm är några av de bolag som visade upp positiva rapporter från det andra kvartalet i juli månad. Sämre gick det bland annat för Orexo.
-
Life science in Stockholm
Sweden has the fourth-largest biotech market in Europe. More than half of its biotechnology enterprise, some 460 companies, is located in the Stockholm region.
-
Take off for this year's fair
More visitors than previously were preregistered when Scanlab and Biotech Forum opened today. But the future of the exhibitions and their design is uncertain.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Fattigt men ljust för branschen
Swedenbios och Arthur D. Littles, ADL, undersökning från i våras är nu sammanställd och life sciencebolag verksamma i Sverige är positiva inför framtiden, men u...
-
Uppsala Bios nya support
Andra länder än Sverige är bättre på att utnyttja pengar från EU: s ramprogram och nu vill Uppsala Bio sporra svenska småbolag att söka pengar. (Uppdaterad)
-
Swedish top scientists to EMBO
Two Swedish top scientists will have a really good chance to influence European life science research from now on. One is from the Karolinska Institutet, and on...
-
Welcome to wonderful Copenhagen
Strategically located, the Danish capital is the focal point of one of the most dynamic regions in Northern Europe. Here are some tips on where to spend your ti...
-
Time to save for survival
The future is bright for the biotech industry. However, the companies need to cut costs immediately if they want to survive the rough economic times.
-
Novo och Astra ligger bra till i internationell kraftmätning
Patentutgångar kommer under de närmaste åren att drabba flera stora läkemedelsbolag, men Astrazeneca och Novo Nordisk hör till de som skymtar ljusglimtar enligt en analys.
BREAKING